Yue Yan, Sijia Yang, Kathleen E. Mach, Guoli Chen, David J. DeGraff, Joseph C. Liao, Pak Kin Wong
The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers ample opportunities for developing effective immunomodulatory therapies. Here we show microbial product cocktails as an alternative class of immunotherapy for cancer. Using freshly resected tumors from bladder cancer patients, an immuno-comparative analysis of recruitment and enhancement assay, and an artificial intelligence-guided optimization workflow, we establish a personalized platform for identifying potent microbial product cocktails that promote recruitment, infiltration, and activation of immune cells for cancer treatment. In an orthotopic mouse bladder cancer model, microbial product cocktails demonstrate immunoenhancement and improve survival rates compared with standard bacillus Calmette–Guérin immunotherapy. Intravesical bacillus Calmette–Guérin (BCG) is an established bacterial immunotherapy for bladder cancer. Here, the authors develop a personalized platform to identify microbial product cocktails that promote immune cell recruitment, infiltration, and activation for improving bladder cancer treatment.